Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved ...
PharmExec

FDA Approves Avlayah for Treatment of Hunter Syndrome

FDA accelerated approval positions Avlayah as the first therapy engineered to cross the blood–brain barrier for MPS ...

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Stifel 2026 Virtual CNS Forum March 17, 2026 2:00 PM EDTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...
ascopubs.org

High transferrin receptor expression marks tumors with increased immune-effector infiltration and expression of targetable checkpoint molecules: Results of a multi-cancer ...

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor ...

Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build

Denali Therapeutics (NASDAQ:DNLI) executives outlined near-term regulatory milestones, commercial launch preparations, and a ...
News Medical

Targeting tumor immunity with transferrin receptor-directed photodynamic therapy

This new article publication from Acta Pharmaceutica Sinica B, discusses a transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through β-catenin/CREB ...